Arbutus Biopharma (ABUS) Preferred Shares (2017 - 2021)

Arbutus Biopharma has disclosed Preferred Shares across 5 years of filings, most recently posting $161.0 million for Q3 2021.

• Preferred Shares for Q3 2021 came in at $161.0 million, up 10.04% year-over-year; the trailing twelve-month figure through Sep 2021 was $161.0 million (up 10.04% YoY), and the FY2020 annual result was $149.4 million, up 8.83% from the prior year.
• Preferred Shares came in at $161.0 million for Q3 2021 at Arbutus Biopharma, up from $155.9 million in the prior quarter.
• In the past five years, Preferred Shares ranged from a high of $161.0 million in Q3 2021 to a low of $49.8 million in Q4 2017.
• The 5-year median for Preferred Shares is $135.8 million (2019), against an average of $132.5 million.
• Across the five-year window, Preferred Shares jumped 153.39% in 2018 and advanced 8.81% in 2021, its largest moves.
• Arbutus Biopharma's Preferred Shares stood at $49.8 million in 2017, then surged by 153.39% to $126.1 million in 2018, then increased by 8.84% to $137.3 million in 2019, then increased by 8.83% to $149.4 million in 2020, then rose by 7.74% to $161.0 million in 2021.
• The last three Preferred Shares figures came in at $161.0 million (Q3 2021), $155.9 million (Q2 2021), and $152.6 million (Q1 2021), per Business Quant data.